Neuberg Diagnostics Unveils Geniee: A Personalized Genomics Platform

GE HealthCare's MIM Software Receives FDA Clearance for New Centiloid Scaling Tool to Quantify Amyloid Plaque in Brain Imaging

FDA Approves Merck's KEYTRUDA® (Pembrolizumab) in Combination with Pemetrexed and Platinum Chemotherapy as a First-Line Treatment for Adults with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)

OncoLens Introduces Real-Time Oncology Patient Identification for Clinical Trials and Essential Services

Biognosys and Thermo Fisher Sign Reselling Agreement for Spectronaut Proteomics Software

TVM Capital Healthcare Invests in Human Longevity Inc. to Drive Global Expansion of Precision Medicine

Circular Genomics Unveils MindLight™: The First SSRI Antidepressant Response Test Based on Brain-Derived Biomarkers

Pfizer Promotes BRAF Mutation Testing in Lung Cancer to Expand Braftovi Market

Immuneel Therapeutics Appoints Amit Mookim as New CEO

Celyad Oncology Appoints Matt Kane as Chief Executive Officer

Amrita Hospital in Faridabad Establishes Center of Excellence for CAR T-Cell Therapy

Exact Sciences' Blood-Based Colon Cancer Screening Data Surpasses Expectations at ESMO

Velsera Technology Achieves Milestone with FDA Approval of Illumina TruSight™ Oncology Comprehensive IVD, Advancing Cancer Diagnostics

ESMO 2024: GSK/iTeos's TIGIT Shows Promise in NSCLC, Intensifying the Competitive Landscape

Strand Life Sciences Introduces Liquid Biopsy Test to Enhance Cancer Diagnosis

Home
/
update
/
details

Amrita Hospital in Faridabad Establishes Center of Excellence for CAR T-Cell Therapy

NextEdge Admin

17 Sep 2024

2 min 19 sec

Amrita Hospital, Faridabad, has launched a Centre of Excellence (CoE) for CAR T-cell therapy, a cutting-edge treatment designed to target specific blood cancers like B-cell non-Hodgkin lymphomas and acute lymphoblastic leukemia. The new center aims to provide advanced immunotherapy to patients in the National Capital Region (NCR).

Dr. Sanjeev Singh, Medical Director of Amrita Hospital, emphasized the institution's role as an early adopter of CAR T-cell therapy, noting its pivotal contribution in optimizing these therapies for patients. He highlighted the hospital's evolution from traditional treatments to stem cell transplants and now CAR T-cell therapy, positioning Amrita as a leader in this next-generation cancer treatment.

Dr. Prashant Mehta, Senior Oncologist, stated that the CoE would enhance the accessibility and scalability of CAR T-cell therapies, resulting in more durable remissions for patients in northern India. He also mentioned that the CoE would support Amrita’s clinical and molecular research, expanding CAR T-cell therapy’s application to solid tumors and autoimmune diseases.

Swami Nijamritananda Puri, Administrative Director, underlined the hospital's commitment to providing affordable, innovative healthcare, guided by the vision of accessible treatment for all. He noted the challenges of introducing new therapies but reaffirmed Amrita’s dedication to advancing cancer treatment in India.

Since the CDSCO’s approval of NexCAR19 in October 2023, more than 100 patients have undergone CAR T-cell therapy, with some survivors remaining in remission for over two years, demonstrating the therapy's potential for long-term success.